Kuros Current Deferred Revenue from 2010 to 2026
| KURN Stock | CHF 25.24 0.24 0.96% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 52.2 K | Current Value 49.6 K | Quarterly Volatility 2.4 M |
Check Kuros Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kuros Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.7 M, Interest Expense of 127.4 K or Selling General Administrative of 5.5 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 10.9. Kuros financial statements analysis is a perfect complement when working with Kuros Biosciences Valuation or Volatility modules.
Kuros | Current Deferred Revenue |
The evolution of Current Deferred Revenue for Kuros Biosciences AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kuros Biosciences compares to historical norms and industry peers.
Latest Kuros Biosciences' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Kuros Biosciences AG over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Kuros Biosciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kuros Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Kuros Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,507,576 | |
| Geometric Mean | 209,604 | |
| Coefficient Of Variation | 160.34 | |
| Mean Deviation | 2,048,132 | |
| Median | 58,000 | |
| Standard Deviation | 2,417,210 | |
| Sample Variance | 5.8T | |
| Range | 5.9M | |
| R-Value | (0.72) | |
| Mean Square Error | 3T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (344,345) | |
| Total Sum of Squares | 93.5T |
Kuros Current Deferred Revenue History
About Kuros Biosciences Financial Statements
Kuros Biosciences investors use historical fundamental indicators, such as Kuros Biosciences' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kuros Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 52.2 K | 49.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kuros Stock Analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.